XML 41 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Equity Incentive Plan (Tables)
6 Months Ended
Jun. 30, 2021
Schedule of Additional Information on Stock Option Grants And Vesting

The following table summarizes additional information on stock option grants and vesting (in thousands):

 

 

 

2019 Plan

 

 

 

Six Months Ended June 30, 2021

 

 

Six Months Ended June 30, 2020

 

Total fair value of stock options granted

 

$

2,293

 

 

$

8,766

 

Total fair value of options vested

 

 

252

 

 

 

-

 

Schedule of Black Scholes model for the Private Warrants

To estimate the fair value of the Private Warrants as of December 31, 2020 and June 30, 2021, the Company used a Black Scholes closed form model, which is a Level 3 fair value measurement. Significant inputs used in the Black Scholes model for the Private Warrants were as follows:

 

 

December 31, 2020

& June 30, 2021

 

 

 

 

 

 

Expected volatility

 

 

16.00

%

Expected term (in years)

 

 

3.97

 

Risk free interest rate

 

 

1.74

%

Dividend yield

 

 

0.00

%

Exercise Price

 

$

11.50

 

Fair value of Common Stock

 

$

8.05

 

 

 

Six Months Ended June 30, 2021

 

 

Six Months Ended June 30, 2020

 

Expected volatility

 

44.06% - 44.61%

 

 

37.63% - 40.98%

 

Expected term (in years)

 

6.0

 

 

6.0

 

Dividend yield

 

0.00%

 

 

0.00%

 

Risk-free interest rate

 

0.70% - 1.00%

 

 

1.43% - 0.45%

 

 

Stock Based Compensation Expense Included In Consolidated Statements of Comprehensive Loss

Stock-based compensation expense is included in the Company’s Consolidated Statements of Comprehensive Loss within the following line items (in thousands):

 

 

 

Three Months Ended June 30, 2021

 

 

Three Months Ended June 30, 2020

 

 

Six Months Ended June 30, 2021

 

 

Six Months Ended June 30, 2020

 

Cost of revenues

 

$

348

 

 

$

326

 

 

$

690

 

 

$

681

 

General and administrative

 

 

410

 

 

 

261

 

 

 

806

 

 

 

491

 

Research and development

 

 

72

 

 

 

67

 

 

 

136

 

 

 

140

 

Sales and marketing

 

 

188

 

 

 

160

 

 

 

364

 

 

 

327

 

Total

 

$

1,018

 

 

$

814

 

 

$

1,996

 

 

$

1,639

 

Restricted Stock Units [Member]  
Schedule of RSUs Activity Under 2019 Plan

The following table summarizes the Company’s RSU activity:

 

Description

 

RSUs

Outstanding

 

Balance at December 31, 2020

 

 

1,290,432

 

Granted

 

 

434,538

 

Vested

 

 

(103,622

)

Forfeited

 

 

(81,656

)

Expired

 

 

-

 

Balance at June 30, 2021

 

 

1,539,692

 

2019 Plan [Member]  
Schedule of Stock Option Activity Under 2019 Plan

The following table summarizes the Company’s stock option activity under the 2019 Plan:

 

Description

 

Options

Outstanding

 

 

Weighted

Average

Exercise

Price

 

 

Weighted

Average

Remaining

Contractual

Term (Years)

 

 

Aggregate

Intrinsic

Value (1)

 

Options Outstanding, December 31, 2020

 

 

4,260,753

 

 

$

8.46

 

 

 

9.0

 

 

$

54

 

Granted

 

 

1,277,771

 

 

 

8.02

 

 

 

 

 

 

 

 

 

Exercised

 

 

(4,676

)

 

 

8.00

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(285,592

)

 

 

8.25

 

 

 

 

 

 

 

 

 

Expired

 

 

(18,017

)

 

 

8.00

 

 

 

 

 

 

 

 

 

Options Outstanding, June 30, 2021

 

 

5,230,239

 

 

$

8.36

 

 

 

8.8

 

 

$

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Vested and Exercisable, June 30, 2021

 

 

1,330,862

 

 

$

8.38

 

 

 

8.4

 

 

$

-

 

Options Vested and Expected to Vest, June 30, 2021

 

 

5,230,239

 

 

$

8.36

 

 

 

8.8

 

 

$

5

 

 

 

(1)

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying Common Stock (as defined below) and the exercise price of outstanding in-the-money options.

Schedule of Black Scholes model for the Private Warrants The following table summarizes the assumptions used in the valuation models to determine the fair value of stock options granted to employees and non-employee directors: